Surgery – Diagnostic testing – Detecting nuclear – electromagnetic – or ultrasonic radiation
Reexamination Certificate
2006-09-19
2006-09-19
Gitomer, Ralph (Department: 1655)
Surgery
Diagnostic testing
Detecting nuclear, electromagnetic, or ultrasonic radiation
C600S436000, C250S363030, C378S065000, C436S169000, C540S145000
Reexamination Certificate
active
07110808
ABSTRACT:
An apparatus and method for subsequent optimization of radiosurgery and radiotherapy is provided. The invention includes administering a metalloporphyrin to the patient, and then creating a 3-dimensional mapping of tissue through use of PET or SPECT. Malignant and pre-malignant tissue has an affinity for the metalloporphyrin. During treatment, real-time images are also provided which are compared to the previous 3-dimensional mapping. Creation of the real-time images is also achieved through PET or SPECT wherein a metalloporphyrin is administered to the patient. Total administration of radiation is calculated by summing radiation from the metalloporphyrins and from the radiosurgery/radiotherapy. The amount of radiation delivered by the metalloporphyrins and by the radiosurgery/radiotherapy are adjustable based on a patient's response to the dual delivery.
REFERENCES:
patent: 3846490 (1974-11-01), Aronova et al.
patent: 3934369 (1976-01-01), Rebeiz
patent: 3973129 (1976-08-01), Blumberg et al.
patent: 4772681 (1988-09-01), Fukuda et al.
patent: 4886831 (1989-12-01), Morcos et al.
patent: 4897444 (1990-01-01), Brynes et al.
patent: 4905670 (1990-03-01), Adair
patent: 4920143 (1990-04-01), Levy et al.
patent: 4977177 (1990-12-01), Bommer et al.
patent: 4997639 (1991-03-01), Aizawa et al.
patent: 5026368 (1991-06-01), Adair
patent: 5043101 (1991-08-01), Gordon
patent: 5079262 (1992-01-01), Kennedy et al.
patent: 5087636 (1992-02-01), Jamieson et al.
patent: 5117466 (1992-05-01), Buican et al.
patent: 5122453 (1992-06-01), Martin et al.
patent: 5143054 (1992-09-01), Adair
patent: 5149708 (1992-09-01), Dolphin et al.
patent: 5162231 (1992-11-01), Cole et al.
patent: 5211938 (1993-05-01), Kennedy et al.
patent: 5234940 (1993-08-01), Kennedy et al.
patent: 5251613 (1993-10-01), Adair
patent: 5270171 (1993-12-01), Cercek et al.
patent: 5283255 (1994-02-01), Levy et al.
patent: 5308608 (1994-05-01), Dolphin et al.
patent: 5308861 (1994-05-01), Aizawa et al.
patent: 5391547 (1995-02-01), Cole et al.
patent: 5418169 (1995-05-01), Crissman et al.
patent: 5422093 (1995-06-01), Kennedy et al.
patent: 5441531 (1995-08-01), Zarate et al.
patent: 5554505 (1996-09-01), Hajek et al.
patent: 5556764 (1996-09-01), Sizto et al.
patent: 5591422 (1997-01-01), Hemmi et al.
patent: 5605805 (1997-02-01), Verwer et al.
patent: 5616342 (1997-04-01), Lyons
patent: 5627040 (1997-05-01), Bierre et al.
patent: 5652114 (1997-07-01), Chu et al.
patent: 5773609 (1998-06-01), Robinson et al.
patent: 5955490 (1999-09-01), Kennedy et al.
patent: 5986693 (1999-11-01), Adair et al.
patent: 6190877 (2001-02-01), Adair
patent: 6235767 (2001-05-01), Kelly et al.
patent: 6358989 (2002-03-01), Kunz et al.
patent: 6387350 (2002-05-01), Goldenberg
patent: 6395016 (2002-05-01), Oron et al.
patent: 6422988 (2002-07-01), Bradshaw et al.
patent: 6422989 (2002-07-01), Hektner
patent: 6566517 (2003-05-01), Miura et al.
patent: 6750037 (2004-06-01), Adair et al.
patent: 0 277 837 (1988-10-01), None
patent: 04330013 (1992-11-01), None
U.S. Appl. No. 10/836,453, filed Apr. 2004, Adair.
Palac et al; Nuclear Medicine Communications, V. 10(11), pp. 841-850, (Nov. 1989) (Abstract Only).
Abstract, Mu Y, et al., “P-S-D-007 Luminescence in the Diagnosis of Exfoliative Cells from Malignant Tumors”, X-P-0021614131, vol. 9, No. 4, 1987, pp. 258-259.
Abstract, Schwartz, G., et al., “Selected Amino Acridines as Fluorescent Probes in Cytochemistry in General and in the Detection of Cancer Cells in Particular”,Analytical and Quantitative Cytology, vol. 4, No. 1, 1982, pp. 44-54.
Abstract, Gardiner, R.A., et al., “Abnormal prostatic cells in ejaculates from men with prostatic cancer: A preliminary report”,British Journal of Urology, vol. 78, No. 3, 1996, pp. 414-418.
Abstract, Bologna, M., et al., “Improved tissue culture method for the study of prostatic carcinoma: A significant diagnostic tool.”,Pathology Research and Practice, vol. 191, No. 9, 1995, pp. 899-903.
Artemov et al.,Cancer Res., 61:3039-3044 (2001).
Fiel et al.,Cancer Letters, 40:23-32 (1988).
Furmanski and Longley,Cancer Res., 48:4604-4610 (1988).
Harisinghani et al.,N. Engl. J. Med., 348(25):2491-2499 (2003).
Koenig et al.,Magnetic Resonance in Medicine, 4:252-260 (1987).
Lyon et al.,Magnetic Resonance in Medicine, 4:24-33 (1987).
Rosenthal et al.,Clin. Cancer Res., 5:739-745 (1999).
van Zijl et al.,Acta Radiologica, 374(supp):75-79 (1990).
Pottier et al.; “Non-Invasive Technique for Obtaining Fluorescence Excitation and Emission SpectraIn Vivo”; Photochemistry and Photobiology; vol. 44, No. 5; pp. 679-687, 1986.
Abstract, Sauter, E.R., et al., “Nipple aspirate fluid: A promising non-invasive method to identify cellular markers of breast cancer risk”,British Journal of Cancer, vol. 76, 1997, pp. 494-501.
Abstract, Sugiyama, M., et al., “Non-invasive detection of bladder cancer by identification of abnormal CD44 proteins in exfoliated cancer cells in urine”, Abstract,Clinical Molecular Pathology, 1995, vol. 48, pp. M142-M147.
Nyamekye et al.; “Photodynamic Therapy of Normal and Balloon-Injured Rat Carotid Arteries Using 5-Amino-Levulinic Acid”;Circulation, vol. 91, No. 2, Jan. 15, 1995, pp. 417-425.
Peng et al.; “5-Aminolevulinic Acid-Based Photodynamic Therapy”;American Cancer Society; 1997; pp. 2282-2305.
Berg et al.; “The Influence of Iron Chelators On the Accumulation of Protoporphyrin IX in 5-Aminolaevulinic Acid-Treated Cells”;British Journal of Cancer; 1996; pp. 688-697.
Noodt et al.; “Apoptosis and Necrosis Induced With Light and 5-Aminolaevulinic Acid-Derived Protoporphyrin IX”;Flow Cytometry; 1996; pp. 22-29.
Malik et al.; “Destruction of Erythroleukaemic Cells by Photoactivation of Endogenous Porphyrins”British Journal of Cancer; 1987; 56; pp. 589-595.
Leon et al.; “Localized Intracoronary Gamma-Radiation Therapy to Inhibit the Rcurrence of Restenosis After Stenting”;The New England Journal of Medicine; Jan. 25, 2001; 344(4); pp. 250-256.
Verin et al.; “Endoluminal Beta-Radiation Therapy for the Prevention of Coronary Restenosis After Balloon Angioplasty”;The New England Journal of Medicine; Jan. 25, 2002; 344(4); pp. 243-249.
Abstract: Leunig et al.; “Fluorescence Photodetection of Neoplastic Lesions in the Oral Cavity Following Topical Application of 5-Aminolevulinic Acid”;Laryngo-Rhino-Otologie; vol. 75, No. 8, Aug. 1996; pp. 459-464.
Firnau et al.; “64Cu Labelling of Hematoporphyrin Derivative for Non-Invasive In-Vivo Measurements of Tumour Uptake”Porphyin Localization and Treatment of Tumors; 1984 Alan R. Liss, Inc.; pp. 629-636.
Webster's II New Riverside University Dictionary, Copyright 1984, 1988, 1994, pp. 490 and 968.
News and Views; Radiolabelled photosensitizers for tumour imaging and photodynamic therapy, B.C. Wilson and J.E. VanLier; XPOO8023295, 459-463.
The Biological Characteristics of a Water Soluble Porphyrin in Rat Lymph Nodes; D.A. Cole, J.A. Mercer-Smith, S.A. Schreyer, J.K. Norman and D.K. Lavallee; XP008023296, 457-464.
Porphyrin Localization and Treatment of Tumors, pp. 629-636; 1984 Alan R. Liss, Inc., XP0080239292.
Chromatographic Analysis and tissue Distribution of Radiocopper-Labelled Haematoporphyrin Derivatives; Brian C. Wilson, Gunter Firnau, W. Patrick Jeeves, Kay L. Brown, Diane M. Burns-McCormick; XP008023291, 72-79.
LandOfFree
Method of optimizing radiosurgery and radiotherapy with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of optimizing radiosurgery and radiotherapy with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of optimizing radiosurgery and radiotherapy with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3589401